Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stiff-person syndrome.

Juliana Lockman1, Ted M Burns

  • 1Ted M. Burns, MD University of Virginia, Department of Neurology, PO Box 800394, Charlottesville, VA 22908, USA. tmb8r@virginia.edu.

Current Treatment Options in Neurology
|April 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatments for Functional Neurological Disorder: A Practical Guide for Program Development.

The Journal of neuropsychiatry and clinical neurosciences·2025
Same author

Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases.

Translational neurodegeneration·2025
Same author

Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU).

Muscle & nerve·2023
Same author

The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events.

PloS one·2022
Same author

Functional seizures: The patient's perspective of a diagnostic and treatment odyssey.

Epilepsy & behavior reports·2022
Same author

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.

Neurology·2021
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Stiff-person syndrome (SPS) is an autoimmune disorder causing muscle rigidity and spasms. Treatment involves symptomatic relief, with immunomodulatory therapies for persistent disability.

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Stiff-person syndrome (SPS) is a rare neurological disorder characterized by axial and appendicular rigidity and painful spasms.
  • Diagnosis is clinical, supported by elevated glutamic acid decarboxylase autoantibody titers, specific electromyography findings, and normal MRI/CSF studies.
  • SPS variants include stiff-limb syndrome, SPS plus (encephalomyelitis), and paraneoplastic associations.

Purpose of the Study:

  • To outline the clinical presentation, diagnostic criteria, and management strategies for Stiff-person syndrome.
  • To discuss the proposed autoimmune etiology and therapeutic approaches for SPS.

Main Methods:

  • Clinical diagnosis based on characteristic rigidity, hyperlordosis, and spasms.
  • Laboratory support: elevated GAD65 autoantibody titers (>20 nmol/L).

Related Experiment Videos

  • Electromyography demonstrating continuous motor unit activity in axial muscles.
  • Exclusionary criteria: normal MRI and cerebrospinal fluid studies.

    • Main Results:

    • Symptomatic treatment with benzodiazepines and/or baclofen is the cornerstone of management.
    • Neuromodulators like antiepileptic drugs and muscle relaxants can be used.
    • For refractory cases, immunomodulatory and immunosuppressive therapies are considered.

    Conclusions:

    • SPS is likely an autoimmune condition, supported by autoantibody presence and response to immunotherapy.
    • Treatment requires a stepwise approach, starting with symptomatic relief and progressing to immunomodulation if needed.
    • Intravenous immunoglobulin has shown efficacy in a randomized controlled trial; other options include steroids, plasma exchange, and chemotherapy.